Dutch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

dihydroartemisinin/misselijkheid

De link wordt op het klembord opgeslagen
Bladzijde 1 van 16 resultaten
BACKGROUND Drug resistance of falciparum malaria is a global problem. Sulphadoxine/pyrimethamine-resistant and mefloquine-resistant strains of falciparum malaria have spread in Southeast Asia at lightning speed in 1980s-1990s, and the Cambodia-Thailand border is one of the malaria epidemic areas

Efficacy of dihydroartemisinin-mefloquine on acute uncomplicated falciparum malaria.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
OBJECTIVE To evaluate the clinical efficacy of dihydroartemisinin-mefloquine on acute uncomplicated falciparum malaria. METHODS Fifty-four patients with symptomatic falciparum malaria were allocated to receive oral dihydroartemisinin at a single dose of 120 mg on day 1, followed by mefioquine, 750
We compared the safety and efficacy of three formulations of dihydroartemisinin for the treatment of acute uncomplicated falciparum malaria in patients who received a total dose of 600 mg dihydroartemisinin over 5 days. The first group was treated by dihydroartemisinin produced and formulated in the

[Efficacy of compound dihydroartemisinin/piperaquine in treatment of uncomplicated falciparum malaria in Myanmar].

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
OBJECTIVE To observe the therapeutic efficacy of compound dihydroartemisinin-piperaquine for treatment of uncomplicated falciparum malaria in Myanmar. METHODS From 2007 to 2008, patients aged 6 to 60 years with uncomplicated P. falciparum infection and parasite density 500 to 200 000

Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND The World Health Organization (WHO) recommends Artemisinin-based Combination Therapy (ACT) for treating uncomplicated Plasmodium falciparum malaria. This review aims to assist the decision-making of malaria control programmes by providing an overview of the relative effects of
Artemisinin-based combination therapies (ACT) are now being adopted as first-line treatments against uncomplicated malaria in sub-Saharan Africa. Between December 2009 and February 2010, the efficacies of two ACT - dihydroartemisinin-piperaquine (DHA-P) and artemether-lumefantrine (AL) - in the

Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Artemisinin-based combination regimens are recommended by WHO for the treatment of uncomplicated Plasmodium falciparum malaria. One such combination comprises the artemisinin derivative dihydroartemisinin and the bisquinolone piperaquine. Eurartesim® is the only dihydroartemisinin/piperaquine
BACKGROUND The widespread use of artesunate-amodiaquine (ASAQ) for treating uncomplicated malaria makes it important to gather and analyse information on its tolerability. METHODS An individual-patient tolerability analysis was conducted using data from eight randomized controlled clinical trials

Four artemisinin-based treatments in African pregnant women with malaria.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Information regarding the safety and efficacy of artemisinin combination treatments for malaria in pregnant women is limited, particularly among women who live in sub-Saharan Africa. We conducted a multicenter, randomized, open-label trial of treatments for malaria in pregnant women in four African
The efficacy-safety and pharmacokinetics of the six-dose regimen of artemether-lumefantrine (Coartem/Riamet; Novartis Pharma AG, Basel, Switzerland) were assessed in a randomized trial in 219 patients (> or = 12 years old) with acute, uncomplicated Plasmodium falciparum malaria in Thailand. One

Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
Objective: The World Health Organization recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria to improve the therapeutic efficacy and limit the choice of drug-resistant parasites. This

Four Artemisinin-Based Treatments in African Pregnant Women with Malaria.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND Information regarding the safety and efficacy of artemisinin combination treatments for malaria in pregnant women is limited, particularly among women who live in sub-Saharan Africa. METHODS We conducted a multicenter, randomized, open-label trial of treatments for malaria in pregnant

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND Concomitant use of anti-malarial and antiretroviral drugs is increasingly frequent in malaria and HIV endemic regions. The aim of the study was to investigate the pharmacokinetic interaction between the anti-malarial drugs, artesunate-mefloquine and the antiretroviral drug, lopinavir

Plasmodium vivax severe imported malaria in two migrants in France.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
With less than one severe case per year in average, Plasmodium vivax is very rarely associated with severe imported malaria in France. Two cases of P. vivax severe malaria occurred in patients with no evident co-morbidity. Interestingly, both cases did not occur at the primary

Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
In Zambia, malaria is one of the leading causes of morbidity and mortality, especially among under five children and pregnant women. For the latter, the World Health Organization recommends the use of artemisinin-based combination therapy (ACT) in the second and third trimester of pregnancy. In a
Word lid van onze
facebookpagina

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

  • Werkt in 55 talen
  • Kruidengeneesmiddelen gesteund door de wetenschap
  • Kruidenherkenning door beeld
  • Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
  • Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
  • Zoek medicinale kruiden op hun effecten
  • Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek

Google Play badgeApp Store badge